Antidepressant Treatment of AIDS Related Depression.
Completed · Phase 2
Conditions studied: Depression
In brief
To test the effectiveness treating AIDS related depression with imipramine hydrochloride. Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status. This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.
Key facts
- Study ID
- NCT00000390
- Run by
- GEIGY Pharmaceuticals
- Last updated by the study team
- 2015-04-23
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patient must be ambulatory and relatively good health. Even if unable to work at least able to partially care care for self and not demented.
- May have been alcoholic or drug abuser 6 months previous.
- Unspecified
- CD4 Unspecified.
You may not qualify if…
- Non ambulatory patients or those requiring extensive help in self care are excluded.
- Non ambulatory patients or those requiring extensive help in self care are excluded.
- Current alcohol or drug abuse.
- Unspecified
Where it is running
- New York Hosp - Cornell Med Ctr — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.